This site is intended for a global audience
Contact Us

Leader Perspectives

PJ Honerkamp, Sleep Business Unit Head

As a long-time leader in sleep medicine, we have come to understand the importance of providing solutions that address patients’ lives holistically, especially for those living with serious, debilitating rare disorders. Read more about how we’re delivering on this promise and supporting the sleep community at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies.

Rob Iannone, Executive Vice President, Global Head of Research and Development

As we continue to make advancements in cancer research, we’re focused on delivering treatment options in areas of oncology with high unmet needs, including HER2-positive biliary tract cancer (BTC), as well as supporting patient communities beyond R&D. Through recent advocacy efforts, in addition to sharing new data at the upcoming ASCO 2024 Annual Meeting, we’re committed to supporting patients throughout their disease journeys.

Ryan Bovia, Vice President, Head of Epilepsy and Movement Disorders Business Unit

March 26th marks Purple Day – a pivotal moment in time to recognize and support the 50 million people around the world who are living with epilepsy. We’re using this day to pause and reflect on the progress that has been made for people in the epilepsy community and advance our purpose to innovate to transform the lives of patients and their families.

Elaina Gartner, Vice President Medical, Late-Stage Development, Oncology Clinical Development, Jazz Pharmaceuticals

In honor of Cholangiocarcinoma Awareness Month in February, we’re raising awareness about biliary tract cancer (BTC), the role HER2 expression plays in this type of cancer, and Jazz’s commitment to supporting patients with rare diseases such as BTC. This month is particularly important for people diagnosed with BTC, as well as their families and caregivers, and we’re highlighting our approach to seeking innovative solutions for them so they can live their lives more fully.

Stefan Faderl, VP, Therapeutic Area Head, Oncology Clinical Development, Jazz Pharmaceuticals

Our presence at SABCS 2023 marks a significant step forward for Jazz as our oncology pipeline continues to evolve to address new tumor types such as breast cancer. We’re excited to gather with leaders in the breast cancer community and share our research, including findings for our HER2-targeted bispecific antibody in HER2+ breast cancer, which reflects our continuous dedication to reshaping cancer care and addressing unmet needs. 

Ryan Bovia

November is National Epilepsy Awareness Month – a milestone that allows us to pause and reflect on both the progress the community has made for people living with this condition and their continued unmet needs. This time of reflection is especially important for people diagnosed with rare forms of epilepsy, as well as their families and caregivers, who are continuing to search for improved therapeutic outcomes.